Arcus Biosciences is no longer the Gilead-optioned multi-asset immuno-oncology platform that defined the last half-decade. The second quarter closed a partner unwind: broad early-stage option rights expired in mid-July, three Gilead board seats were given back in August, and the TIGIT late-stage program was wound down after futility. What remains is a Hayward company that now lives or dies on casdatifan, a wholly owned HIF-two-alpha inhibitor that management is trying to install as backbone therapy across every line of kidney cancer.
The print looks like collapse only if last year's Gilead catch-up is treated as a run rate. Revenue of $41 million sat against a year-ago figure swollen by a $143 million accounting catch-up when Gilead handed back the adenosine program. Strip that event and the real story is a cost reset: research spending fell as the TIGIT studies closed, cash still stood at $775 million, and management still guides runway into the second half of twenty twenty-eight. The tension is whether that cash is buying a kidney-cancer franchise or merely funding a more expensive version of the same clinical-stage burn.
The next two reporting periods resolve a single question. Do the platform-study readouts across first-line, second-line, and late-line kidney cancer show a deeper, more durable HIF blockade than Merck's already-approved belzutifan, or does the partner retreat leave Arcus as a well-funded single-asset story with a shrinking collaboration umbrella? Shares closed at $25 on the publication date, inside a range that has more than doubled off the twelve-month low. That price already treats casdatifan as more than an option.